Comparative Pharmacology
Head-to-head clinical analysis: SEROSTIM LQ versus ZOMACTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEROSTIM LQ versus ZOMACTON.
SEROSTIM LQ vs ZOMACTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK-STAT signaling pathways, leading to increased insulin-like growth factor-1 (IGF-1) production, which promotes linear growth and anabolic effects.
ZOMACTON is a recombinant human growth hormone that binds to growth hormone receptors on cell surfaces, activating intracellular signaling cascades (primarily JAK-STAT pathway) leading to increased IGF-1 production, which mediates growth and metabolic effects including linear growth, protein synthesis, and lipolysis.
0.2 mg/kg subcutaneously once daily for 4 weeks in HIV-associated wasting; for growth hormone deficiency, 0.005 mg/kg subcutaneously once daily initially, titrated to 0.01 mg/kg once daily.
Intramuscular or subcutaneous injection: 0.1-0.3 mg/kg/day (up to 0.6 mg/kg/day) divided into 1-2 doses. Typical adult dose for growth hormone deficiency: 0.2 mg/kg/day subcutaneously.
None Documented
None Documented
2.6 hours (subcutaneous administration); terminal half-life is approximately 2-3 hours, requiring daily dosing for growth hormone deficiency.
Terminal elimination half-life: 2-3 hours after subcutaneous administration; clinically, this necessitates daily or more frequent dosing.
Renal: >90% of somatropin is metabolized in the liver and kidneys; less than 1% of the administered dose is excreted unchanged in urine.
Renal: nearly 100% of absorbed dose, mostly as intact hormone; negligible biliary/fecal elimination.
Category C
Category C
Growth Hormone
Growth Hormone